Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Clasificación en acciones #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Precio por acción
$451.59
Capitalización bursátil
$114.70B
Cambio (1 día)
-2.36%
Cambio (1 año)
-11.89%
País
US
Comercio Vertex Pharmaceuticals Incorporated (VRTX)

Categoría

Ratio P/E de Vertex Pharmaceuticals Incorporated (VRTX)
Ratio P/E al March 2026 TTM: 30.14
Según los últimos informes financieros y el precio de las acciones de Vertex Pharmaceuticals Incorporated, el P/E actual (TTM) de la empresa es 30.14. Al final de 2023, la empresa tenía un P/E de 28.97.
Historial del ratio P/E de Vertex Pharmaceuticals Incorporated desde 2000 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 30.14 -115.57%
2024 -193.61 -768.33%
2023 28.97 30.12%
2022 22.26 -7.86%
2021 24.16 6.69%
2020 22.65 -52.59%
2019 47.77 137.69%
2018 20.10 -85.80%
2017 141.54 -188.38%
2016 -160.15 194.95%
2015 -54.30 43.69%
2014 -37.79 0.67%
2013 -37.54 -54.76%
2012 -82.97 -136.06%
2011 230.08 -2,573.28%
2010 -9.30 -19.61%
2009 -11.57 24.62%
2008 -9.29 21.26%
2007 -7.66 -62.60%
2006 -20.48 68.70%
2005 -12.14 143.00%
2004 -5.00 23.34%
2003 -4.05 -63.36%
2002 -11.05 -60.02%
2001 -27.65 -77.34%
2000 -122.02 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
10.72 -64.45%
DK
17.03 -43.49%
US
30.44 0.98%
BE
33.07 9.72%
AU
38.30 27.06%
NL
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.